Search Results

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.

• Authors : Zhang, Yunlin^1,2 (AUTHOR); Patel, Ruchi P.^1,2 (AUTHOR); Kim, Ki Hyun³ (AUTHOR)

• Source: Molecular Cancer. 12/9/2023, Vol. 22 Issue 1, p1-23. 23p.

Record details

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

• Authors : Atish Kizhakeyil; Nurmahirah Binte Mohammed Zaini; Zhi Sheng Poh

Subjects: DDX3X mutation; Hematolymphoid malignancy; Prognosis

• Source: Molecular Cancer, Vol 20, Iss 1, Pp 1-7 (2021)

Record details

ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.

• Authors : Qiao Zhang¹ (AUTHOR); Zhe Yang¹ (AUTHOR); Zhuqing Jia¹ (AUTHOR)

• Source: Molecular Cancer. 2014, Vol. 13 Issue 1, p181-195. 15p. 14 Diagrams, 1 Chart, 7 Graphs.

Record details

Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas.

• Authors : Minglong Zhou¹ ; Fadlelmola, Faisal M.¹ ; Cohn, Jason B.²

• Source: Molecular Cancer. 2008, Vol. 7, Special section p1-11. 11p. 2 Color Photographs, 2 Black and White Photographs, 4 Charts, 3 Graphs.

Record details

Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines.

• Authors : Fadlelmola, Faisal M.¹ ; Minglong Zhou¹ ; de Leeuw, Ronald J.²

• Source: Molecular Cancer. 2008, Vol. 7, Special section p1-13. 13p. 4 Color Photographs, 2 Charts, 1 Graph.

Record details

EBV-positive Hodgkin lymphoma is associatedwith suppression of p21cip1/waf1 and a worseprognosis.

• Authors : Ting-Yun Liu¹; Shang-Ju Wu²; Mi-Hsin Huang¹

• Source: Molecular Cancer. 2010, Vol. 9, p32-43. 12p.

Record details

Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B)

• Authors : Gascoyne Randy D; Karsan Aly; Steidl Christian

Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282

• Source: Molecular Cancer, Vol 9, Iss 1, p 14 (2010)

Record details

Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas

• Authors : Faisal M. Fadlelmola; Minglong Zhou; Diponkar Banerjee

Subjects: Cancer Research; Cytoplasm; CD30

• Source: Molecular CancerMolecular Cancer, Vol 7, Iss 1, p 12 (2008)

Record details

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

• Authors : Kizhakeyil, Atish; Zaini, Nurmahirah Binte Mohammed; Poh, Zhi Sheng

Subjects: DIFFUSE large B-cell lymphomas; PROGNOSIS; NON-Hodgkin's lymphoma

• Source: Molecular Cancer; 10/15/2021, Vol. 20 Issue 1, p1-7, 7p

Record details

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy.

• Authors : Liu, Zongzhi^1,2,3,4,5 (AUTHOR); Li, Xiang^5,6 (AUTHOR); Gao, Yibo¹ (AUTHOR)

• Source: Molecular Cancer. 5/16/2023, Vol. 22 Issue 1, p1-17. 17p.

Record details